Enforcement Report - Week of June 7, 2023
Enforcement Report - Week of March 22, 2023
Enforcement Report - Week of January 25, 2023
Health Canada has granted approval for Bausch Health and Glenmark Pharmaceuticals subsidiary Glenmark Specialty’s Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) as a symptomatic therapy for moderate to severe seasonal allergic rhinitis (SAR).
Health Canada has approved Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) by Bausch Health and Glenmark for the symptomatic treatment of moderate-to-severe Seasonal Allergic Rhinitis (SAR) and associated ocular symptoms in adults, adolescents and children aged six years and older, the companies said in a joint statement.
Glenmark's partner Hikma launches specialty drug Ryaltris in US
LONDON and MAHWAH, N.J.and MUMBAI, India, Aug. 30, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical company, and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation driven global pharmaceutical company, announced the launch of RYALTRIS™ (olopatadine hydrochloride and mometasone furoate nasal spray) in the US. RYALTRIS™ is approved by the US Food and Drug Administration (FDA) for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older. This launch builds upon Hikma's leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US.
Enforcement Report - Week of August 17, 2022
Enforcement Report - Week of July 6, 2022